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Abstract
Background: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy for identifying
patients at increased risk from the pre-cancerous lesion Barrett’s oesophagus (BE) is not clear. The Cytosponge, a novel
non-endoscopic sponge device, combined with the biomarker Trefoil Factor 3 (TFF3) has been tested in four clinical
studies. It was found to be safe, accurate and acceptable to patients.
The aim of the BEST3 trial is to evaluate if the offer of a Cytosponge-TFF3 test in primary care for patients on long term
acid suppressants leads to an increase in the number of patients diagnosed with BE.
Methods: The BEST3 trial is a pragmatic multi-site cluster-randomised controlled trial set in primary care in England.
Approximately 120 practices will be randomised 1:1 to either the intervention arm, invitation to a Cytosponge-TFF3
test, or the control arm usual care. Inclusion criteria are men and women aged 50 or over with records of at least 6
months of prescriptions for acid-suppressants in the last year. Patients in the intervention arm will receive an invitation
to have a Cytosponge-TFF3 test in their general practice. Patients with a positive TFF3 test will receive an invitation for
an upper gastro-intestinal endoscopy at their local hospital-based endoscopy clinic to test for BE.
The primary objective is to compare histologically confirmed BE diagnosis between the intervention and control arms
to determine whether the offer of the Cytosponge-TFF3 test in primary care results in an increase in BE diagnosis
within 12 months of study entry.
Discussion: The BEST3 trial is a well-powered pragmatic trial testing the use of the Cytosponge-TFF3 test in the same
population that we envisage it being used in clinical practice. The data generated from this trial will enable NICE and
other clinical bodies to decide whether this test is suitable for routine clinical use.
Trial registration: This trial was prospectively registered with the ISRCTN Registry on 19/01/2017, trial number
ISRCTN68382401.
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Background
Incidence of oesophageal adenocarcinoma (EAC) has
increased six-fold since the 1970s and carries a dismal
prognosis (13% 5-year survival) despite advances in neo-
adjuvant therapy and surgery [1]. Clinical guidelines have
focused on urgent referral for those with alarm symptoms,
specifically dysphagia, chronic gastro-intestinal bleeding,
weight loss, persistent vomiting, anaemia or an epigastric
mass [2]. Routine referral is advised for those with reflux
symptoms that persist despite recommended lifestyle and
pharmacological management strategies [3]. General
Practice (GP) referral rates vary widely and low endoscopy
referral rates have been linked with poor outcomes from
oesophageal cancer [4].
Approximately 3 to 6% of individuals with reflux pre-
dominant symptoms may have Barrett’s oEsophagus
(BE), the precursor lesion to EAC. However, only 20 to
25% of patients with BE are diagnosed [5]. It is estimated
that the burden of EAC could be reduced by up to 50%
as a result of increasing the proportion of individuals
with reflux predominant symptoms who are investigated
[6]. This is a formidable task since dyspepsia and gastro-
oesophageal reflux disease (GERD) affect between 5 and
20% of the population [7] and account for up to 10% of
GP consultations in the UK.
Endoscopic treatment of BE, which progresses through
dysplastic and superficially invasive stages, can prevent
the development of EAC [8]. Indeed, endoscopic treat-
ment is now recommended for patients with low and high
grade dysplasia following new randomised controlled trial
evidence [9, 10]. By identifying and referring to endoscopy
those most likely to have BE, it should be possible to
reduce mortality from EAC in patients with reflux who
would not otherwise receive endoscopy.
Cytosponge diagnostic test for Barrett’s oESophagus
A non-endoscopic diagnostic modality for BE has been
developed which involves a device called the Cytosponge™
combined with molecular biomarker Trefoil Factor 3
(TFF3) [11] (Fig. 1).
The Cytosponge™ consists of a Class I, non-CE marked
3 cm diameter, polyester, medical grade mesh sphere on a
string, compressed within a gelatine capsule. The capsule
is swallowed while holding onto the string. After 5 min,
the gelatine capsule has dissolved allowing the sphere to
expand. Using the string the sphere is pulled from the
stomach to the oesophagus and mouth thus collecting
cells from the whole of the BE segment [12], as well as
from the squamous oesophagus and oropharynx. The
sample is put into a preservative, processed, and assessed
for the presence of BE via immunohistochemical staining
for TFF3.
A series of four clinical studies have been carried out
so far with the following findings (see Table 1). First, no
serious adverse events were attributed to the Cytosponge™
after administering this test over 2000 patients, showing
that it is a safe intervention [11, 13–16]. Second, the
Cytosponge™ is acceptable to patients with a mean score
of 6.0 (95%CI 5.0–8.0) on a visual analogue scale from
zero (worst experience) to 10 (best experience) reported
by patients [11, 13–16]. Third, the Cytosponge interven-
tion was shown to be transferable to the NHS: 27 nurses
were trained with a single training session in 11 sites
and sample processing was run in an NHS pathology
laboratory [13, 17]. Fourth, a feasibility study conducted
in 504 patients in 11 general practices showed that the
intervention can be applied to primary care [13]. Fifth,
the Cytosponge™-TFF3 test was found to be accurate
for diagnosing BE regardless of patient cohort or study
setting. Last, this test is cost-effective in comparison to
the usual care. A micro-simulation model suggested a
gain of 0.015 QALYs (Quality adjusted life years) and
an incremental cost effectiveness ratio (ICER) of $15,700
per QALY for Cytosponge™ versus endoscopic diagnosis of
BE followed by endoscopic treatment [18].
Fig. 1 (a) Cytosponge™ expanded (left) and in gelatin capsule (right)
(b) representative picture of positive TFF3 staining in a sample from
a patient with BE (× 20 magnification)
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Rationale
Our long-term vision is for the Cytosponge™-TFF3 tech-
nology to be adopted as a triage test within the standard
primary care clinical pathway for patients on treatment
with acid suppressants (proton pump inhibitors (PPIs)
or H2 receptor antagonists (H2RAs)) who do not fulfil
the referral criteria for endoscopy. This strategy will
increase the proportion of patients diagnosed with BE,
and in turn allow for endoscopic therapy and monitoring
for those at greatest risk of EAC.
Objectives
Primary and secondary objectives, and endpoints are
summarised in Table 2 and described below.
Primary objectives
To compare histologically confirmed BE diagnosis between
intervention and the control arms to determine whether
the offer of the Cytosponge™-TFF3 test in primary care
results in an increase in BE diagnosis within 12 months of
study entry.
Secondary objectives
The main secondary objectives are to evaluate the cost
and cost-effectiveness of the Cytosponge™-TFF3 test versus
usual care. Other secondary objectives include confirming
the safety and diagnostic accuracy of the Cytospon-
ge™-TFF3 test and determining the uptake in primary care.
Inviting 10% of BEST3 participants for a research endos-
copy will enable us to assess the diagnostic accuracy of the
Cytosponge™-TFF3 test in primary care. We will also assess
the acceptability of the Cytosponge™-TFF3 test to patients,
GPs and practice nurses, and their experiences of its use in
primary care. Long term objectives are to confirm the
prevalence and incidence of BE, EAC and cancer of the
gastric cardia in a primary care population consulting with
reflux predominant symptoms and to undertake modelling
to predict the reduction in EAC related mortality from this
strategy.
Methods
Design
This is a pragmatic multi-site cluster randomised controlled
trial where approximately 120 general practices will be
randomised 1:1 to either the intervention or control arm
(Fig. 2). Anonymised data will be collected from eligible
patients in both arms at baseline and 1 year post entry into
the study. Patients will be informed about being entered
into BEST3 data collection by letter. Patients in the inter-
vention arm will receive an invitation for a Cytosponge™-
TFF3 test in their general practice. Patients with a positive
TFF3 test will receive an invitation for an upper gastro-in-
testinal (GI) endoscopy at their local hospital-based en-
doscopy clinic to test for BE. In addition to the
TFF3-positive patients, 10% of the patients in each arm
(who have not had an endoscopy since the start of the
trial) will be randomly selected to be invited for an
endoscopy at approximately 12 months.
Study setting
120 (but up to 150 practices as the project requires) will
be recruited from six to seven clinical research networks
(CRNs): Eastern, North Thames, North East and North
Cumbria, Yorkshire and Humber, but other regions
may participate as required. For Information Technology
reasons, only practices using Egton Medical Information
Systems (EMIS) or TTP’s SystmOne, the two most common
systems, will be included in the study.
Participants
Patients at participating general practices will be selected
by GP staff. Inclusion and exclusion criteria for the
different stages of BEST3 are outlined in Table 3. In brief,
male and female patients aged 50 and over with records of
at least 6 months of prescription for acid-suppressant
medication (PPI or H2RA) in the last year will be eligible
for BEST3 data collection. Patients who also have records
of prescriptions for non-steroidal anti-inflammatory drugs
(NSAIDs) or an upper GI endoscopy in the previous 5
years will be excluded. These eligibility criteria are based
on GP database records, which are not always complete.
Table 1 Studies summary, sensitivity and specificity of the Cytosponge™-TFF3 test per segment length
Study Ref n# Publication Year Study type Setting BE length Sensitivity % (95% CI) Specificity % (95% CI)
Pilot [14] 2008 Cohort 2ary care ≥C1 78.0 (64.0–89.0) 94.0 (87.0–98.0)
BEST1 [12] 2010 Prospective 1ary care ≥C1 73.3 (44.9–92.2) 93.8 (91.3–95.8)
≥C2 90.0 (55.5–99.7) 93.5 (90.9–95.5)
BEST2 [13] 2014 Case:control 2ary care ≥C1 79.5 (75.9–82.9) 92.4 (89.5–94.7)
≥C2 83.9 (80.0–87.3)
≥C3 87.2 (83.0–90.6)
CASE1 [15] 2015 Cohort 2ary care ≥C1 or ≥M3
≥C3
95.4 (86.9–98.9)
96.8 (83.7–99.5)
N/A
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However, as they are used to increase the power of the
trial and not for safety reasons, they only have to be
applied based on data as it is available.
Number of participants
A minimum of 9000 patients will be entered into the
BEST3 trial.
Randomisation
All patients aged 50 and over who have received at least
6 months’ supply of an acid suppressant drug (either PPI
or H2RA) in the last year will be identified by carrying
out a database search on coded clinical information. If a
practice database search identifies more than 100 eligible
patients, 100 patients will be randomly selected to be in-
cluded in the trial. Once the practice consents to partici-
pate in BEST3, each practice will be randomised via
block randomisation and stratified by number of eligible
patients. Three groups of approximately 40 practices are
proposed, each with the following number of patients:
 Stratum 1 (small practices): 50–60
 Stratum 2 (medium practices): 61–74
 Stratum 3 (large practices): 75–100.
The number of patients invited in each stratum and/or
the number of strata used might be increased depending
on uptake of the Cytosponge. Once a practice has consented
Fig. 2 BEST3 trial design overview showing both BEST3 anonymous data collection steps (green) and intervention, Cytosponge™-TFF3 test or
upper GI endoscopy related procedures (blue)
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to participate in the trial, a database search will be carried
out to determine the number of eligible patients and as part
of which stratum they will be randomised. Practices will be
randomised 1:1 between the intervention and control arms.
Randomisation will be balanced by geographical area to en-
sure that Cytosponge™ clinics will have similar number of
bookings in each area. However, as the number of eligible
patients in the different practices who will participate is not
definite, the number of practices per stratum and the num-
ber of strata overall will be adjusted as necessary. The
process will be managed so that number of practices in each
arm and each stratum will be equal and that the numbers of
participants per practice within a stratum will be similar.
Dates and duration of the trial
Start date: September 2016.
Total duration: 36 months.
Consent procedures
Patients will be entered into different stages of the trial
at different levels of consent.
Consent at practice level (opt in)
Firstly, consent will occur at practice level. GPs will pro-
vide consent that the practice can be randomised and
participants contacted within the BEST3 Trial. GPs will
furthermore consent to aggregate anonymised patient
data being collated from their practice database and pa-
tient notes.
Introductory letter provided to patients about use of
anonymous data (BEST3 data collection)
All participants across both arms will receive an infor-
mation letter from their practice outlining that anonym-
ous data collected in the course of their routine care will
be included in the study. They will have 14 days to opt
out of having their anonymised data collected and ana-
lysed as part of BEST3.
Written consent for BEST3 intervention and endoscopy (opt
in written consent)
Written (individual-level) consent will be obtained be-
fore carrying out any procedures. All participants receiv-
ing a Cytosponge™–TFF3 test or endoscopy as part of
the study will be individually-consented to have this pro-
cedure and for the associated clinical data to be
collected.
BEST3 introductory letter and anonymous data collection
BEST3 introductory letter
Eligible patients to be included in the study will be sent
the introductory letter about the BEST3 data collection
Table 3 Inclusion and Exclusion criteria for the BEST3 trial
Inclusion criteria Exclusion criteria for
BEST3 data collection Cytosponge procedure Upper GI endoscopy
• Male and female
• Aged ≥50
• Records of ≥6 months
of prescription for
acid-suppressant medication
in the last year
• Recorded regular prescriptions
of NSAIDs
• Recorded upper GI endoscopy
in the previous 5 years as
identified from the practice
database
• Recorded diagnosis of a
current or previous
oro-pharynx, oesophageal or
gastro-oesophageal tumour
• Recorded diagnosis of BE
• Unable to attend the GP surgery
• Deemed not fit enough by their
GP, including lacking capacity
• Meeting the guidelines for an urgent
endoscopy referral according to
NICE guidelines
• Recorded diagnosis of an oro-pharynx,
oesophageal or gastro-oesophageal
tumour (T2 staging and above), or
symptoms of dysphagia
• Difficulty in swallowing due to a known
cerebrovascular accident or neurological
disorder
• Recorded oesophageal varices, cirrhosis
of the liver
• Inability to temporarily discontinue
anti-thrombotic medication prior to
procedure
• Having eaten and drank within the
preceding 4 h
• Received prior surgical intervention to
the oesophagus
• Known pregnancy
• Lacking capacity to provide informed
consent
• Upper GI endoscopy during the
study period
• Severe hypertension (e.g. systolic
> 200 diastolic > 100)
• Myocardial infarction or any cardiac
event within the previous 6 months
• Cerebrovascular event or other
neurological disorder where
swallowing has been affected within
the previous 6 months
• Any previous treatment such as
Photodynamic therapy (PDT) or Radio
Frequency Ablation (RFA) to the
oesophagus
• Anticoagulation therapy/ medication
on day of procedure (warfarin,
heparin or tinzaparin) according to
local guidelines
• Other medical condition: low platelets
or blood abnormalities that may cause
excessive bleeding post procedure
• Eaten or drank within the previous
6 h
• Preference for sedation and has not
brought anyone to accompany
them at home. Follow local guidelines
• Known pregnancy
• Lacking capacity to provide informed
consent
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from their treating clinician (see above). This letter will
additionally explain that they may receive an invitation
to participate in later stages of the study.
Aggregate data collection for BEST3 trial
Study entry will be defined as 14 days after the date the
introductory letter is sent. At this point demographic
and medication data will be extracted from the GP data-
base for every patient entered into the study. This dataset
will then be aggregated into sex and 10-year age groups
(Table 4).
Follow-up data will be collected 12 months after study
entry for all patients in each practice, irrespective of
study arm and whether they had a Cytosponge™-TFF3
test. Where a new diagnosis of BE or EAC, and / or an
endoscopy has been coded in the medical records, data
will be extracted from endoscopy and pathology reports
and entered into the aggregate data table manually
(Table 4). Full baseline data will also be extracted.
Long term follow-up
When suitable anonymisation models become available,
long term cancer registration and mortality data will be
obtained from NHS Digital and the NHS Health and
Social Care Information Centre (HSCIC) or equivalent.
Data sent from HSCIC to QMUL will always be anon-
ymised and aggregated by practice. Individually-consented
participants in the trial may have their longer-term heath
status followed up via data held by NHS Digital, HSCIC
or its successor, the Office of National Statistics, Public
Health England and other national databases.
BEST3 intervention: Cytosponge™-TFF3 test
Patient invitation to BEST3 intervention
All participants in the intervention arm, who have not
opted out of the study, will receive a second letter from
their GP team inviting them to have the Cytosponge™-TFF3
test. This communication will include a standalone
Cytosponge™ information leaflet (Additional file 1:
Figure S1). This leaflet was developed based on
Table 4 Baseline and follow up data to be collected
Baseline data extract 12 month follow up extract
Time point/period Variable Time point/period Variable
Baseline Sex Baseline Sex
Age Age
Obesity records Baseline and
12 months (where available)
Obesity records
Smoking status Smoking status
Alcohol consumption Alcohol consumption
Previous 12 months PPI / H2RA prescriptions Previous 12 months PPI / H2RA prescriptions
Other prescription medication: Aspirin,
COX2i, antibiotics for H. pylori eradication
Other prescription medication: Aspirin, COX2i,
antibiotics for H. Pylori eradication
Heartburn and / or GERD related
symptoms
Heartburn and / or GERD related symptoms
Number of GP and practice nurse visits at
home and at the practice
Number of endoscopy or GI referrals
Diagnosis of BE
Diagnosis of EAC or pre-malignant conditions
Diagnosis of benign oesophageal conditions
Records on any upper GI specific procedures,
e.g. endotherapies or oesophagectomies
Anonymised endoscopy reports including
pathology reports for BE and OC diagnosis; and
benign conditions via a tick box (EoE, candida,
inflammation, ulcer slough, squamous dysplasia,
herpes, other)
Type of referral: emergency via A&E, 2 week
wait / urgent, routine and in or out patient
(either form GP records or endoscopy report)
Number of biopsies (from endoscopy reports)
Anonymised letters from upper GI consultants
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findings from a qualitative study on the acceptability
of the Cytosponge™ test [19] followed by several rounds of
review by patient and public involvement (PPI) represen-
tatives. Once a participant has expressed interest by
returning a reply slip or telephone call, the participant will
receive a telephone call to further assess eligibility based
on a short questionnaire. If eligible, an appointment
will be arranged. The participant will then be sent a
Cytosponge™ patient information sheet, consent form
and appointment confirmation.
Cytosponge™ clinic procedure
Cytosponge™ clinics for participants from several practices
will be held by either a CRN or local practice nurse with
appropriate medical cover in place. Participants will be
asked to refrain from eating and drinking for 4 h. Once
consent has been obtained, the nurse will complete a
questionnaire on demographic and clinical information
and the previously validated GERD Impact Scale (GIS)
with the participants [20] using case report forms (CRFs)
in the BEST3 Database.
Patients will be asked to swallow the capsule with
water. The capsule reaches the stomach while
remaining attached to the string which is held onto by
the patient or nurse (and which is affixed to a card pre-
venting inadvertent swallowing of the entire string). In
the stomach the capsule is left for up to 5 min where it
dissolves allowing the sponge to expand to its full size.
It is then withdrawn by the research nurse using the
string, and as it does so collects cells from the lining of
the oesophagus. The retrieved sphere is placed in pre-
servative liquid. Linked anonymised samples will be
sent directly from the practice to the pathology labora-
tory to be processed and analysed for TFF3 and H&E.
If a patient fails to swallow the capsule, they will be
asked to try again. In the event of a Cytosponge™ de-
tachment or an obvious bleed the research nurse will
immediately inform the GP as the patient falls under
their duty of care for medical assessment. Following
medical assessment, the GP’s normal emergency pro-
cedures will be followed. The research nurse will tele-
phone all participants who received the Cytoponge™
at 7 days post-procedure to assess safety and report
adverse events.
Storage and analysis of Cytosponge™ samples
Cytosponge™ samples will be sent directly from GP sites
to Cambridge University Hospitals NHS Foundation Trust
Research Tissue Bank (CUHTB) to be processed into
Formalin Fixed Paraffin Embedded (FFPE) blocks for
TFF3 testing, and H&E analysis as described previously
for the BEST2 trial [14].
Cytosponge™-TFF3 results
Patients will be informed about their Cytosponge™-TFF3
results by a standardised Cytosponge™ feedback letter
from their GP within four to 6 weeks. Where the test is
a low-confidence negative result, i.e. the sample fails in
processing or is equivocal, the patient may be invited for
a repeat test at a suitable location depending on local
capacity. Other benign conditions of the oesophagus will
be reported with the TFF3 result.
Endoscopies
Invitation for endoscopies - intervention arm: TFF3-positive
patients
Patients with a positive TFF3 test will be contacted by their
GP to inform them of the result and offer an endoscopy
examination to confirm the diagnosis. If this is agreed by
the patient the GP informs the research nurse to arrange
the procedure at the local endoscopy unit.
Invitation for research endoscopies - 10% of patients who
do not require diagnostic endoscopy (all arms)
10% of the total number of study participants who have
not had an endoscopy during the study will be invited
for a research endoscopy at 12 months after entry into
the study, including participants who have declined the
original Cytosponge™-TFF3 intervention. Since BEST3 will
be assessing the acceptability of endoscopy compared
with Cytosponge™-TFF3, the intervention here will be
“invitation to endoscopy”. Participants to be invited will
be selected at random using the random selection function
in practice databases. They will receive an invitation letter
for a research endoscopy at their local hospital-based
endoscopy clinic including an endoscopy-specific BEST3
Patient Information Sheet and a consent form.
Endoscopy procedures
Standard trans-oral endoscopy following BSG guidelines
[21] for diagnosis of BE will be carried out. During the
procedure the endoscopist will note the diagnostic endo-
scopic landmarks for BE using a standard protocol and
in line with the Seattle protocol [22]:
 For all endoscopies where BE is found, biopsies will
be collected (in all 4 quadrants) every 2 cm
according to surveillance guidelines. In addition,
endoscopically-suspicious areas will be targeted for
biopsies.
 A further two biopsies from the gastro-oesophageal
junction (GOJ) will be collected (below the z-line)
for research purposes from both BE positive and
patients with a TFF3 negative test.
 All biopsy samples will be processed and analysed by
the local pathologist according to standard clinical
practice including for benign conditions.
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 Study participants will be informed about endoscopy
findings in the usual way via a letter from the
gastroenterologist copied to their GP.
 Endoscopic images will be requested of every GOJ
and newly diagnosed BE to try to exclude
misdiagnosed hiatus hernias and intestinal
metaplasia (IM) at normal appearing GOJ.
Diagnosis of BE
Diagnosis of BE as the primary endpoint will be defined
at three different levels of certainty:
 Diagnosis by the endoscopist or gastroenterologist
following BSG guidelines
∘ > 3 cm likely correct;
∘ < 3 cm more suspect unless biopsy with IM;
 Confirmed by study pathologist or gastroenterologist
∘ >C1 or >M3 +IM on biopsy;
 IM on biopsy
∘ any length.
As a secondary endpoint we will also use a scoring
system for BE according to severity (Table 5).
TFF3 positive patients will also be asked to provide a
saliva sample using the Oragene DNA kit at their
endoscopy appointment. These samples will be stored
for future genetic research.
Acceptability measures- intervention group only
Patient acceptability measures
Baseline Participants receiving the Cytosponge™-TFF3
test will be asked to complete a baseline questionnaire
consisting of:
I. STAI-6, a short-form of the state scale of the
Spielberger State-Trait Anxiety Inventory (STAI);
this 6-item self-completed scale has been widely
used to measure short-lived anxiety in relation to
health experiences [23]. To aid the appointment
process, and to ensure that the state being
measured accurately reflects views about the
procedure, the questionnaire will be provided to
the patient prior to consent in the clinic waiting
room area. If the patient does not go on to consent
into the study, their questionnaire response will be
disposed of securely.
Once consent has been obtained:
II. Lifestyle and family history questionnaire, covering
education, history of smoking and alcohol, and any
family history of heartburn, BE, oesophageal cancer
and any other type of cancer.
III. Perceived risk of oesophageal cancer, using 2 items
which have been widely used for other cancer risk
assessments to assess perceived risk of developing
EAC and perceived risk compared with a person of
the same age (relative risk) [24];
7–14 day follow-up Seven to fourteen days post-study
consultation, all participants receiving the Cytosponge™-
TFF3 test will be either sent an email or text message with
a link to an online questionnaire (or mailed a questionnaire
as preferred). This questionnaire will consist of:
I. the Inventory to Assess Patient Satisfaction, used
following flexible sigmoidoscopy screening,
amended for the Cytosponge™-TFF3 test, and
validated using face validation with 8 patients, who
were either at high risk of BE or have had the
Cytosponge™-TFF3 test; this has a 5 point ordinal
scale with 22 items [25];
II. a visual analogue scale (VAS) in which 0 represents
“Completely unacceptable” and 10 represents
“Completely acceptable” [13];
III. Perceived risk of oesophageal cancer [24];
IV. STAI-6 [23].
If the follow-up questionnaire has not been returned
after 2 weeks, a reminder will be sent to participants
who have provided an e-mail address.
Intervention acceptability for patients and health care
professionals
Patients
Some participants from intervention practices will be
interviewed to increase understanding of patient views
on the Cytosponge™-TFF3 test and its use in the primary
care setting. Up to 30 patients across a range of ages and
including both men and women, will be interviewed
within six to 8 weeks of their trial consultation. Patients
will be interviewed in their own home or a place of
their choosing. They will provide written consent prior
to interviews commencing.
Table 5 Proposed BE scoring system
Score BE severity
0 Pathology report not available
1 Intestinal metaplasia (IM) on biopsy and endoscopic
findings not seen in categories below
2 C1 or C0 M3 + IM
3 C2 or more, C0 M4 or more +IM
4 C3 or more
5 Low grade dysplasia (LGD)
6 High grade dysplasia (HGD) or T1a cancer
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Data will be audio-recorded and transcribed profes-
sionally. It will remain confidential and will not be
shared with their GP. Data will be analysed using
Thematic Analysis [26], supported by NVivo. We expect
the following themes to be explored in the analysis:
patient views of acceptability of Cytosponge™-TFF3 test
use in primary care, and patient understandings and
perceptions of ‘risk’ in relation to their symptoms. As
qualitative analysis is an inductive and iterative process,
further themes will evolve throughout the analytical
process.
Healthcare professionals
GPs Semi-structured interviews with up to 20 GPs from
intervention practices will be undertaken to identify and
gain an understanding of the facilitators and constraints
influencing use of the Cytosponge™ in primary care routine
clinical practice. GPs will be recruited purposively to sam-
ple as widely as possible (region, gender, age, trainer status,
rural / urban location). GPs can choose to be interviewed
face-to-face or by telephone. Those who are interviewed
by telephone will be asked to provide verbal consent at the
beginning of the interview and also complete a written
consent form to be returned by post. Data collection,
transcription and analysis will be undertaken in a similar
way to the patient interviews.
Research nurses All research nurses involved in delivering
the intervention will be asked to complete a short on-line
questionnaire at the beginning and end of their involvement
in the study. This will focus on issues around their training,
patient recruitment to their clinics, and delivering the inter-
vention. We will also undertake semi-structured interviews
with up to 20 research nurses from intervention practices,
to identify and gain an understanding of the facilitators and
constraints influencing use of the Cytosponge™-TFF3 test in
primary care routine clinical practice. Research nurses will
be recruited to sample as widely as possible (region, gender,
age, trainer status, rural / urban location), for a telephone
interview. The methods of data collection, transcription
and analysis will be identical to the GP interviews. In
addition, we will undertake descriptive analyses of the
questionnaire data, and use both datasets in a mixed
methods analysis to look for overarching themes.
Involvement of public and patient involvement
representatives
The BEST3 study design and key documents (introduc-
tory letter, Cytosponge™-TFF3 test leaflet, and PIS) were
discussed with a group of seven PPI representatives based
at Cambridge University Hospitals NHS Foundation
Trust. This group reviewed all patient facing materials.
Their advice will be used to further guide any changes to
the design of the study and study materials. There are two
active lay members of the BEST3 trial steering committee
(TSC). As part of the TSC, they are involved in the
remainder of the trial, including analysis of results and
dissemination of findings.
Statistics and data analysis
Sample size calculations
The sample size calculation is based on the following
assumptions:
i. BE prevalence in individuals eligible for the study is
4–5%;
ii. 10% of patients in the usual care arm will be
referred to endoscopy for clinical reasons (after
excluding urgent referral);
iii. The prevalence of BE in patients referred to
endoscopy in the usual care arm is 6%;
iv. Uptake of the Cytosponge™ test is currently
expected to be 50%;
v. Cytosponge™-TFF3 sensitivity is 85% [14];
vi. Endoscopy sensitivity is 100%.
The assumed 4% prevalence of BE in individuals
eligible for the study was based on the BEST1 trial,
which reported 3% in a population, but included patients
with less severe GORD compared with the BEST3 trial
[13]. Since only 50% of patients in the Cytosponge™ arm
are predicted to have the Cytosponge™ test and patients
who do not take up the offer of the test will have the
same management as if they were in the usual care arm
we only expect 2.0% of patients in the intervention arm
to be diagnosed with BE. Furthermore, we expect 0.6%
of patients in the usual care arm to be diagnosed with
BE. For a 90% power (not allowing for clustering) com-
paring 0.6% with 2.0%, we would need 3028 individuals
(1514 in each arm).
To account for the fact that individuals within a cluster,
here a GP practice, might be more similar to each other
than to individuals in other clusters, the number of partic-
ipants required for an individually randomized trial has to
be increased. The sample size calculations were adjusted
for cluster randomization using the variance inflation
factor (VIF) [27]. We allowed for variation in practice size
and adjusted the sample size calculations for three groups
of practices recruiting either 50–60, 61–74 and 75–100
patients. Allowing for intra-cluster correlation of 0.025, an
overall coefficient of variation of 0.2, and mean cluster
sizes of 55, 68 and 88 the VIF was estimated as 2.4, 2.7
and 3.3 respectively. Multiplying the VIF with the
sample size estimated for individual randomization for
each stratum, we would need a total of 84881 pa-
tients. If we are recruiting three groups of 40 prac-
tices with 50–60, 61–74, or 75–100 patients each,
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then 120 practices will result in approximately 90%
power. Assuming 50% uptake, this would result in
2122 patients having the Cytosponge™ test. If the up-
take is lower, the overall number of patients entered
into BEST3 will be increased so that still a total of
2122 patients will have the Cytosponge test.
Statistical analysis
Primary endpoint
Null hypothesis The BE detection rate at 12 months
(excluding any found on random exit endoscopies) is the
same in the intervention (Cytosponge™-TFF3 test) arm
and the control (usual care) arm.
Alternative hypothesis The BE detection rate at
12 months is not the same in the intervention
(Cytosponge™-TFF3 test) arm compared with the
control (usual care) arm.
To determine whether the invitation to the Cytosponge™-
TFF3 test leads to an increase in the number of patients
diagnosed with BE compared with the usual clinical care
pathway we will compare BE diagnosis between intervention
and the control arms in all patients entered into the study.
We shall compare the proportions of BE between the two
groups at 12 months after study entry using a generalised
estimating equation (GEE) with BE diagnosis as the binary
outcome comparing the two arms as fixed effects with
adjustment for age, gender, BMI, and length and dose
of acid suppressive treatment together with cluster as a
random effect. We will use both the assumed intra-class
correlation (0.025) and the estimated intra-class correl-
ation. Statistical significance will be based on a two-sided
test with alpha equal to 5%.
Secondary endpoints (all to be estimated together
with (nominal) 95% Confidence Intervals):
(1) To estimate the diagnostic accuracy of the
Cytosponge™ in primary care the sensitivity will be
calculated as the proportion of TFF3 positive tests
in patients with endoscopy confirmed BE (gold
standard). The specificity will be calculated as the
proportion of TFF3 negative tests in endoscopy
confirmed BE negative patients amongst the 10%
participants randomly invited to endoscopy from
TFF3 negative patients.
(2) To confirm the prevalence and incidence of BE and
cancer stage diagnosis in the intervention and
control arms for 10 years: Long term follow up data
will allow Cox proportional hazard model analysis
to compare oesophageal cancer and death rates.
(3) The acceptability of both Cytosponge™ and
endoscopy tests will be assessed as the proportion of
patients willing to have the test among patients offered
the test. 95% confidence intervals (Clopper-Pearson)
will be used.
Economic evaluation
Primary endpoint
To gain an in-depth understanding of the health econom-
ics of the Cytosponge™-TFF3 test we will undertake a
detailed analysis of the cost and cost-effectiveness of the
Cytosponge™-TFF3 test versus usual care from the
perspective of the NHS and personal social services. For
the cost analysis, cost components will include costs of
diagnosis using the Cytosponge™-TFF3 test, endoscopies
and biopsies, endotherapy, oesophagectomy, and follow-
up in primary and secondary care. Volume of resource use
data will be collected from practice records up until
12 months after study entry. Unit costs will be taken from
published sources such as NHS Reference Costs, the
British National Formulary, and the Personal and Social
Services Research Unit (PSSRU). We will calculate mean
(SD) and median (IQR) costs for both study arms for each
cost component and all components combined.
Cost-effectiveness will be measured in terms of the
incremental cost per QALY gained. We will adapt a
previously-developed decision analytic model which
compared the cost-effectiveness of three strategies:
Cytosponge™ screening with confirmatory endoscopy,
endoscopy alone, and no screening, for 50 year-old
men with GERD. The parameters for prevalence of BE,
sensitivity and specificity of screening, uptake of the
Cytosponge-TFF3 test, costs and utilities will be updated
to reflect the BEST3 data. For these and all other parame-
ters, including disease progression and management strat-
egies, we will search the literature for updated evidence.
We will extend the modelled population to also include
women over 60 years, obtaining gender/age-specific
parameters from BEST3 or searches of the literature
where necessary. We will also undertake value-of-infor-
mation (VoI) analyses, based on the notion that investing
in further research on probabilities of events, HRQL and
costs will reduce decision uncertainty about the
cost-effectiveness of the Cytosponge-TFF3 test. This will
include both the expected value of perfect information
(EVPI) and the expected value of partial perfect informa-
tion (EVPPI). The latter focusing on individual model
parameters or groups of parameters.
As well as looking at total costs, costs will be disaggre-
gated by sector since this may affect implementation of
the Cytosponge™-TFF3 test. Using epidemiological data
on the national incidence of reflux predominant symp-
toms plus cost data from the present study we will also
undertake a budget impact study to calculate what the
total cost would be to the NHS if the Cytosponge™-TFF3
test was rolled out nationally.
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Pilot phase and 6-month milestone review
The study design described here is the original design
submitted in the first version of the protocol for Health
Research Authority approval including ethical review.
This protocol was used for the pilot phase of BEST3,
which consisted of the first 6 practices, to evaluate the
feasibility of this design. The study design was then
amended based on the findings from the these practices
(uptake = ~ 30%; male: female ratio = 46:54%) (Table 6).
In brief, patients will receive one reminder about their
invitation to make a Cytosponge™-TFF3 test appoint-
ment. Furthermore, we may adopt a shorter follow up
period for practices recruited later in the trial using a
simulation tool to ensure parity across datasets. This will
allow timely completion of the trial. Overall, the pilot
phase showed that the study design was logistically
sound and that the full study could go ahead.
Due to the continuing low uptake of less than 30% fur-
ther amendments were made after the 6-month milestone
review (Table 7).
Firstly, to obtain sufficient power without greatly
expanding the number of participants and practices re-
quired, we plan the addition of an individually randomised
group to the current design. Practices already setup or
trained to take part in the cluster-randomised arm will be
permitted to continue with this randomisation method.
Newly engaged practices will randomise using individual
randomisation methods. The sample size calculations have
also been updated to include patients in the intervention
arm with a false-negative Cytosponge™-TFF3 test as
having the same chance of a BE diagnosis via routine
endoscopy as in the control arm (10%). This adjustment
and the updated uptake of the Cytosponge™-TFF3 test
allowed us to estimate that about 1.4% patients in the
intervention arm will be diagnosed with BE within 1 year
of follow-up. Requiring 90% power and a significance level
of 0.05% gives am updated sample size of 6764 individu-
ally randomised patients. The VIF for practices rando-
mised up to now is 3.72, whereas we are using a VIF of 4.5
for practices which have not been randomised yet as we
do not know the number of recruited patients yet. One
individually randomised participant would therefore be
equivalent to 3.72 or 4.5 cluster randomised participants.
Based on confirmed and projected numbers of partici-
pants in cluster-randomised practices, we anticipate
11,816 patients from 100 practices contributing the
equivalent of 2924 individually randomised patients.
That would leave 3840 to be recruited from practices
employing individual randomisation and a total sample
size of 15,656 participants overall.
Secondly, due to small numbers of smaller practices,
stratification by both area and practice size has resulted in
imbalances in arm allocations for some areas. Stratifica-
tion by practice size will not be taken into account during
randomisation anymore, but in the analysis instead.
These changes will ensure that the sample size will be
sufficiently large to detect differences in BE diagnosis be-
tween the two arms and that the study will be completed
in the time frame required.
Discussion
The BEST3 trial is a multi-site cluster-randomised con-
trolled trial to evaluate the ability of the Cytospon-
ge™-TFF3 test to identify BE among patients with
gastro-oesophageal reflux predominant symptoms not
meeting guidelines for referral. This study design is set
within the MRC framework for the design and evalu-
ation of complex interventions [17]. The reasons for
choosing this design over other designs are:
1. We are not proposing this as a screening test per
se, but as a triage test in people being treated for
GERD symptoms with an acid suppressant drug.
2. We are not looking at death from EAC because that
would require too big a study and it was not
considered feasible when discussed with experts.
3. We considered directly comparing the
Cytosponge™-TFF3 test to endoscopy, but have
rejected that option because we do not envisage
endoscopy ever becoming the usual care for the
majority of people with GERD. Apart from anything
else, there are simply not enough endoscopists.
Additionally, BEST2 has established that the
sensitivity to BE of the Cytosponge with TFF3
staining is very high.
Table 6 Amendments to the study protocol post pilot phase
Pilot study findings Amendments to study protocol
Female to male ratio slightly higher than 50:50 overall If the proportion of females to males consistently exceeds 55:45 within the overall
cohort, the study team may institute a 50:50 split for females: males in line with
known BE prevalence, at the discretion of the Trial Statistician.
Cytosponge™ appointment uptake < 50% Patients will receive a total of one reminder in the form of a letter, phone call or text
message.
Time required for practice and patient recruitment might
take longer for each practice than anticipated
Practices recruited in the latter stages of the trial may adopt a 6 month follow-up
period to allow timely completion of study activities with a simulation tool used
to ensure parity across the datasets.
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4. The key question is to know how the use of the
Cytosponge™-TFF3 test would work in practice.
Hence, we need a pragmatic clinical trial and the
most appropriate control arm is “usual care”.
5. We considered individual randomisation in the
original trial design, but rejected it because we were
planning to offer the Cytosponge prospectively to
patients who consulted about reflux. As some
patients would have had more than one
consultation during the recruitment period there
was a risk that they would get randomised more
than once. Furthermore, it might have been difficult
for GPs to remember which arm a patient would have
been in, and how to advice them. As we are now
recruiting prevalent patients, these issues would not
occur. However, cluster randomisation was initially
chosen as it makes the day to day management of the
trial easier for general practice teams.
6. There is also a “mechanistic” element to the trial.
People are also interested in what might be the
features of individuals who have a false negative
Cytosponge™-TFF3 test and what other benign
diseases (of the oesophagus or the stomach) would
be diagnosed or missed by offering the
Cytosponge™-TFF3 test to patients. Hence, we
propose offering endoscopy for research purposes
to a sample (10%) of patients.
7. Analysis of a CPRD cohort has shown that patients
with at least 6 months of prescriptions for an acid
suppressant are the most suitable for this trial, as
they had the highest conversion rate to BE
(manuscript in preparation). Eligible patients will
therefore be identified and invited based on a GP
database search.
8. Informing patients in the usual care arm about this
increased risk and a new diagnostic tool for the
diagnosis of BE, but not giving them the
opportunity of having this test, could result in
increased patient worry.
9. A qualitative study carried out to aid in the design
on the BEST3 trial showed that the majority of
participants were not aware of the increased risk of
BE and oesophageal cancer [19]. Some participants
felt that telling patients who are being invited to
have the Cytosponge™-TFF3 test about the link
between GERD, BE and cancer would scare them.
Furthermore, usual care arm patients might be
requesting the Cytosponge™-TFF3 test in practices
where it is not available or endoscopies creating
additional burden for endoscopy services. Therefore,
patients in both arms will first only be informed
about the BEST3 anonymous data collection, but
not told about the Cytosponge™-TFF3 test. Patients
in the BEST3 intervention arm will then be
separately invited to the Cytosponge™-TFF3 test.
The PPI representatives based at Cambridge
University Hospitals felt this study design was
appropriate.
With the incidence of EAC having increased dramatic-
ally over the last 30 to 40 years and it being the highest in
the UK worldwide, this test has the potential to reduce the
number of late diagnoses and therefore increase 5-year
survival significantly. The BEST3 trial is a well powered
pragmatic trial testing the use of the Cytosponge-TFF3
test in the same population that we envisage it being used
in clinical practice and will be reasonably short lasting
only 3 years. The data generated from this trial will enable
Table 7 Amendments to the study protocol post 6 months milestone review
Milestone review findings Amendments to study protocol Details
Cytosponge appointment uptake 27%: Substantial
impact on sample size as number of practices
would have to be increased to ~ 200
1) Sample size amended
- Using uptake = 27%
- including patients with false negative
Cytosponge test diagnosed with
BE during 12-month follow-up:
(1–0.85)*0.6%
2) Additional individual randomisation
arm added to reduce the sample size
- Individual randomisation sample size (without
adjusting for cluster randomisation): 6764
- Variance inflation factor (VIF) for confirmed and
projected sample sizes are 3.72 and 4.5, respectively.
1 individually randomised participant would therefore
be equivalent to 3.72 or 4.5 cluster randomised
participants
- Practices already commenced set up on the cluster
randomisation design allowed to continue to
randomise in a cluster fashion
- Sample size will be adjusted depending on number
of patients in cluster randomised group
Due to small number of smaller practices,
stratification by both area and practice size
has resulted in imbalances in arm allocations
for some areas
Stratification by practice size will not be
taken into account during
randomisation but in the analysis
instead
- To simplify randomisation and avoid any further
imbalances for remaining cluster randomisation
practices
- Analysis: the primary analysis will be a stratified test of
proportions taking into account the variation inflation
within each stratum.
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NICE and other clinical bodies to decide whether this test
is suitable for clinical use.
Endnotes
1The sample size in the protocol originally submitted
for ethics review was 8988 due to an error, which has
been corrected here.
Additional file
Additional file 1: Figure S1. Cytosponge™ information leaflet. This
leaflet was designed based on the findings from a qualitative study
investigating the acceptability of and information preferences on this test
among patients with GERD. A combination of text and visual illustrations
was used to provide easily accessible information on the Cytosponge-TFF3
procedure, the link between GERD, BE and EAC, and BEST3. (PDF 669 kb).
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